Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

July 1, 2024

Waltham, MA – July 1, 2024 – Innoviva Specialty Therapeutics, Inc. (IST), a wholly-owned subsidiary of Innoviva, Inc. (NASDAQ: INVA) focused on developing and commercializing critical care and infectious disease therapies, announced today that Patricia Drake has been appointed as Chief Commercial Officer. In her new role, she will play a key role in shaping the company’s commercial strategy and driving growth of the company’s commercial portfolio of infectious disease and critical care products, which include XACDURO® (sulbactam-durlobactam), XERAVA® (eravacycline) and GIAPREZA® (angiotensin II).

“Patricia’s appointment as our new Chief Commercial Officer marks the beginning of a new phase of growth and success for IST,” said Matt Ronshiem, PhD, President of Innoviva Specialty Therapeutics, Inc. “Her strategic vision for the company and proven track record make her an exceptional addition to our organization. Patricia’s leadership and valuable experience will be crucial in developing strong relationships with customers, colleagues, and partners and guiding our team to new levels of success.”

Ms. Drake is a highly accomplished life science leader who brings unique experience and achievements to Innoviva Specialty Therapeutics. Her strong leadership background, encompassing strategy, marketing, market access, sales, and commercial operations, is a testament to her capabilities. During her 32-year tenure at Merck, she successfully led commercial organizations across diverse global markets and product portfolios, which included antiviral, oncology, antifungal, and antibiotic products and multiple global business units spanning North and South America and the Nordics.

“I am excited to be joining this dynamic organization at a crucial point in the company’s commercial growth as we look forward to an anticipated NDA submission for the company’s investigational therapy, zoliflodacin,” said Patricia Drake. “I am honored to have the opportunity to build upon the great work that has been accomplished and lead the Commercial team into the next phase of portfolio growth. Our success can significantly impact millions of people in need of new therapeutic options for difficult-to-treat infectious diseases and critical care needs.”

Before joining Innoviva Specialty Therapeutics, Ms. Drake served as the SVP and Chief Commercial Officer at the biopharmaceutical company, Trevena, Inc. She also held significant leadership roles with various global healthcare companies, including CEO and Managing Director of MSD Finland, Global Human Health Strategy Officer at Merck & Co., and the business unit leader for hospital and specialty business in Merck Canada.


About Innoviva Specialty Therapeutics, Inc.

Innoviva Specialty Therapeutics, Inc. a subsidiary of Innoviva, Inc., is focused on delivering innovative therapies in critical care and infectious disease. Innoviva Specialty Therapeutics’ products, through its affiliate, La Jolla Pharmaceutical Company, include GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Innoviva Specialty Therapeutics’ products, through its affiliate, Entasis Therapeutics Inc., include XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). For more information about Innoviva Specialty Therapeutics, please visit here.


Forward Looking Statements

This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, GIAPREZA®, XERAVA® and XACDURO® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus (“COVID-19”); the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31,

2022 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission (“SEC”) and available on the SEC’s website at Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.


Media Contact:

David Patti
Corporate Communications
Innoviva, Inc.
(908) 421-5971